Hordenine
Based on 2 publication(s) in Google Scholar
Hordenine (Ordenina; Peyocactine) is a multifunctional alkaloid with oral activity and blood-brain barrier penetration. Hordenine inhibits LPS-induced phosphorylation of p38, JNK, ERK1/2, p65, IκB, and AKT, prevents p65 nuclear translocation, and suppresses inflammatory cytokines and mediators. Hordenine promotes M2 macrophage polarization, restores blood-milk barrier integrity, alleviates oxidative stress by reducing ROS and MDA, and attenuates LPS-induced lung injury and pulmonary edema. Hordenine inhibits cAMP production, CREB phosphorylation, and MITF expression, thereby suppressing melanin synthesis in melanocytes and reconstructed epidermis. Hordenine activates the Wnt/β-catenin signaling pathway, promotes dermal papilla cell proliferation and hair shaft elongation, and accelerates hair regeneration. Hordenine activates DRD2, acts as a D3R partial agonist, α2A-AR full agonist, and 5-HT2A-R antagonist, and inhibits SERT and DAT. Hordenine inhibits α-synuclein accumulation and ameliorates motor deficits in Parkinson's disease models. Hordenine limits alcohol intake, reduces relapse drinking behavior, and modulates alcohol-induced conditioned place preference. Hordenine can be used for research on mastitis, skin pigmentation, acute lung injury, foodborne diseases, hair loss, Parkinson's disease, bacterial infections, and alcohol use disorder.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.88%
- CAS. Nr.: 539-15-1
- Formel: C10H15NO
- Molecular Weight:165.24
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Hordenine
MoreAlle TNF Receptor Isoform-spezifische Produkte anzeigen
MoreAlle Dopamine Receptor Isoform-spezifische Produkte anzeigen
MoreAlle Adrenergic Receptor Isoform-spezifische Produkte anzeigen
MoreAlle 5-HT Receptor Isoform-spezifische Produkte anzeigen
MoreAlle α-synuclein Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
|
ERK1 |
ERK2 |
IL-6 |
IL-1β |
TNF-α |
iNOS |
COX-2 |
D3 Receptor 6.6 μM (EC50) |
D3 Receptor 6.9 μM (Ki) |
Alpha-2A adrenergic receptor 7.4 μM (EC50) |
Alpha-2A adrenergic receptor 11 μM (Ki) |
5-HT2A Receptor 3.1 μM (Ki) |
In Vitro
Hordenine (25-200 μM; 2 h) shows no cytotoxicity in EpH4-Ev cells at experimental concentrations of 2-100 μM, but affects cell viability at 200 μM[1].
Hordenine (100 μM; 0-8 h) activates the AMPK/Nrf2/HO-1 signaling cascade in EpH4-Ev cells[1].
Hordenine (0.5-100 μM; 1 h/5 days) inhibits melanin content in human epidermal melanocytes by downregulating the expression of MITF, tyrosinase, TRP-1, and TRP-2, and inhibiting CREB phosphorylation, reduces melanin levels in reconstructed epidermis, inhibits tyrosinase activity, and suppresses cAMP production[2].
Hordenine (12.5-200 μM; 48 h) promotes the proliferation of mouse primary dermal papilla cells in a dose-dependent manner[5].
Hordenine (25-50 μM; 10 consecutive days) significantly enhances the colony-forming ability of primary mouse dermal papilla cells at a concentration of 50 μM[5].
Hordenine (25-50 μM; 24 h) increases the proportion of proliferating (Ki67-positive) primary mouse dermal papilla cells, promotes nuclear translocation of β-catenin, elevates the gene expression of key DPC activity markers (ALP, Versican, and Wnt3a), activates the gene expression of the Wnt/β-catenin signaling pathway, and increases ALP protein expression[5].
Hordenine (2-50 μM; 24 h) dose-dependently activates DRD2 in live 293T-Tango-PB cells, with a maximum effective concentration of 50 μM[6].
Hordenine (0-90 μM; 15 min) inhibits cAMP production in HEK293T cells expressing DRD2, with an IC50 of 5.546 μM[6].
Hordenine (25-50 μM; 7 days) attenuates age-related α-synuclein accumulation in C. elegans strain NL5901 via a DRD2-dependent pathway[6].
Hordenine binds to multiple GPCRs with low micromolar affinity, exhibiting the highest affinity for the 5-HT2A receptor (Ki = 3.1 μM) and the D3 receptor (Ki = 6.9 μM)[7].
Hordenine binds to human SERT (Ki = 4.0 μM) with higher affinity than to human DAT (Ki = 30 μM)[7].
Hordenine acts as a potent partial agonist at D3R (EC50 = 6.6 μM; Emax = 70%), a weak partial agonist at α1A-AR (EC50 = 38 μM; Emax = 23%), and a neutral antagonist at 5-HT2A R (Emax < 5%)[7].
Hordenine is a full agonist of the α2A-adrenergic receptor (EC50 = 7.4 μM; Emax = 109%)[7].
Hordenine (25-100 μM; 2 h) attenuates LPS (HY-D1056)-induced inflammatory responses at the mRNA level in EpH4-Ev cells by decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokines, reduces the expression of the pro-inflammatory enzymes iNOS and COX-2, and alleviates the activation of the TLR4-MAPK/NF-κB inflammatory signaling pathway as well as oxidative stress[1].
Hordenine (50-75 μg/mL; 1 h pre-treatment) inhibits the secretion of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in LPS-stimulated RAW264.7 macrophages, downregulates the mRNA expression of pro-inflammatory mediators, and upregulates M2 macrophage markers, inhibits the activation of AKT, NF-κB, and MAPK signaling pathways, and reduces the protein expression of iNOS and COX-2[3].
Hordenine (75 μg/mL; 1 h pretreatment) inhibits LPS-induced nuclear translocation of p65 in RAW264.7 macrophages[3].
Hordenine (0.5-1.0 mg/mL; 48 h) inhibits quorum sensing in Pseudomonas aeruginosa PAO1 in a concentration-dependent manner by reducing the production of the signaling molecules C4-HSL and 3-oxo-C12-HSL, with an inhibition rate of up to 79% for C4-HSL at 1.0 mg/mL[4].
Hordenine (0.5-1.0 mg/mL; 24 h) reduces biofilm formation in Pseudomonas aeruginosa PAO1 by up to 31% at subinhibitory concentrations without affecting planktonic cell viability[4].
Hordenine (0.5-1.0 mg/mL; 24 h) significantly inhibits the production of QS-related virulence factors (protease, elastase, pyocyanin, rhamnolipid, alginate, and pyoverdine) in Pseudomonas aeruginosa PAO1 in a concentration-dependent manner[4].
Hordenine (0.5-1.0 mg/mL; 24 h) inhibits swimming and swarming motility of Pseudomonas aeruginosa PAO1 in a concentration-dependent manner[4].
Hordenine (1.0 mg/mL; 24 h) inhibits the expression of key QS-related genes (lasI, lasR, rhlI, rhlR) in Pseudomonas aeruginosa PAO1, with the most significant effect being a 60% downregulation of lasR[4].
Hordenine (25-50 μM; 9 days) alleviates 6-OHDA (HY-B1081A)-induced locomotor deficits in C. elegans strain N2[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:EpH4-Ev mouse mammary epithelial cells
-
Concentration:25, 50, 100, 200 μM
-
Incubation Time:2 h pretreatment; 24 h LPS stimulation
-
Result:Exerted a notable impact on cell viability at 200 μM.
Showed no cytotoxic effect at 25, 50, and 100 μM.
-
Cell Line:EpH4-Ev mouse mammary epithelial cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:2 h pretreatment; 24 h LPS stimulation
-
Result:Suppressed the LPS-induced increase in mRNA levels of TNF-α, IL-1β, and IL-6.
Further increased the level of IL-10.
-
Cell Line:EpH4-Ev mouse mammary epithelial cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:2 h pretreatment; 24 h LPS stimulation
-
Result:Alleviated the LPS-triggered elevation of iNOS and COX-2 expression.\nDose-dependently reduced the expression of TLR4 and phosphorylated expression of p65 and IκBα.
Alleviated the phosphorylation levels of p38, JNK, and ERK.
Alleviated p65 nuclear translocation.
-
Cell Line:EpH4-Ev mouse mammary epithelial cells
-
Concentration:100 μM
-
Incubation Time:0, 1, 2, 4, 8 h
-
Result:Enhanced activation of the AMPK/Nrf2/HO-1 pathway after 2-4 h pretreatment.
Promoted Nrf2 translocation into the nucleus.
AMPK inhibitor compound C inhibited AMPK phosphorylation, Nrf2 upregulation, and HO-1 expression.
Nrf2 inhibitor retinoic acid inhibited Nrf2 activation, HO-1 expression, the decrease in MDA content, and the increase in CAT activity and GSH/GSSG ratio.
-
Cell Line:human epidermal melanocytes (Cascade Biologics)
-
Concentration:0.5, 5, 50, 100 μM
-
Incubation Time:1 h
-
Result:Inhibited cAMP production in a concentration-dependent manner.
-
Cell Line:human epidermal melanocytes (Cascade Biologics)
-
Concentration:0.5, 5, 50, 100 μM
-
Incubation Time:1 h and 5 days
-
Result:Suppressed CREB phosphorylation.
Decreased MITF expression significantly in a concentration-dependent manner.
Inhibited the production of tyrosinase, TRP-1, and TRP-2.
At 100 μM, tyrosinase/β-actin, TRP-1/β-actin, and TRP-2/β-actin ratios were reduced to approximately 0.35, 0.4, and 0.35, respectively.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:50, 75 μg/mL
-
Incubation Time:1 h (pre-treatment); 12 h (LPS stimulation)
-
Result:Suppressed the LPS-induced increases in TNF-α, IL-6, and IL-1β protein levels.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:50, 75 μg/mL
-
Incubation Time:1 h (pre-treatment); LPS stimulation
-
Result:Reduced the LPS-induced mRNA expression of IL-6, TNF-α, iNOS, and COX-2.
Promoted the expression of M2 macrophage marker genes Arg-1, Ym-1, and CD206.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:50, 75 μg/mL
-
Incubation Time:1 h (pre-treatment); 1 h (LPS stimulation)
-
Result:Reduced the LPS-induced increases in iNOS and COX-2 protein levels.
Alleviated the increased phosphorylation levels of AKT, p65, IκB, p38, ERK1/2, and JNK induced by LPS.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:75 μg/mL
-
Incubation Time:1 h (pre-treatment); 12 h (LPS stimulation)
-
Result:Inhibited the LPS-induced nuclear translocation of p65.
-
Cell Line:primary mouse dermal papilla cells (DPCs)
-
Concentration:0, 12.5, 25, 50, 100, 200 μM
-
Incubation Time:48 h
-
Result:Showed safety at 200 μM.
Significantly increased cell proliferation at 12.5, 25, 50, and 100 μM, with the highest increase observed at 50 μM.
-
Cell Line:primary mouse dermal papilla cells (DPCs)
-
Concentration:0, 25, 50 μM
-
Incubation Time:24 h
-
Result:Increased the percentage of Ki67-positive DPCs in a dose-dependent manner, with counts rising from 10 (control) to 28 (25 μM) and 39 (50 μM) per 100 cells.\nGreatly promoted the nuclear entrance of β-catenin in DPCs compared with the controls.
-
Cell Line:primary mouse dermal papilla cells (DPCs)
-
Concentration:0, 25, 50 μM
-
Incubation Time:24 h
-
Result:Markedly upregulated the mRNA levels of ALP, Versican, and Wnt3a in a dose-dependent manner.\nMarkedly upregulated the mRNA expression of β-catenin, Lef-1, Axin2, and Cyclin D1 in a dose-dependent manner.
-
Cell Line:primary mouse dermal papilla cells (DPCs)
-
Concentration:0, 25, 50 μM
-
Incubation Time:24 h
-
Result:Markedly upregulated the protein levels of ALP in a dose-dependent manner.\nSignificantly increased the protein levels of p-GSK3β, β-catenin, Lef-1, Axin2, and Cyclin D1.
In Vivo
Hordenine (10-15 mg/kg; i.p.; single administration; 1 h before LPS modeling) attenuates LPS-induced acute lung injury in mice in a dose-dependent manner by inhibiting inflammation and the production of inflammatory cytokines[3].
Hordenine (1-2 mM; topical application; daily; 25 days) accelerates the entry into the hair follicle anagen phase and hair regeneration in a depilation-induced mouse alopecia model by activating the Wnt/β-catenin signaling pathway[5].
Hordenine (30-100 mg/kg/day; p.o.; daily; 12 days) significantly ameliorates MPTP (HY-15608)-induced motor deficits and gait abnormalities in mice, rescues 44.4% of the climbing time, and restores multiple gait parameters[6].
Hordenine (100 mg/kg; p.o.; daily; 22 days) significantly ameliorates motor deficits in the 6-OHDA-induced hemiparkinsonian mouse model, reducing climbing time by 22.2% and traversal time by 34.2%[6].
Hordenine (50 mg/kg; i.p.; once daily; for 4 consecutive days) attenuates persistent alcohol intake in mice and prophylactically reduces relapse behavior after withdrawal[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (25-30 g, 7-8 weeks old, female)[1]
-
Dosage:50 mg/kg/day
-
Administration:p.o.; daily; 14 days
-
Result:Reduced histopathological scores in mammary tissue from 3.75 to 1.75.
Attenuated the LPS-induced increase in MPO activity.
Reduced levels of pro-inflammatory mediators (IL-6, TNF-α, IL-1β, COX-2, iNOS) while elevating the anti-inflammatory cytokine IL-10.
Restored the integrity of the blood-milk barrier by upregulating the expression of tight junction proteins ZO-1, occludin, and claudin-3.
Inhibited the LPS-induced phosphorylation of key proteins in the TLR4-MAPK/NF-κB pathway while activating the AMPK/Nrf2/HO-1 antioxidative pathway.
Mitigated the LPS-induced increase in MDA content and restored decreased CAT activity, GSH/GSSG ratio, and SOD activity.
Altered the composition of intestinal microbiota, increasing the abundance of Lactobacillaceae, S24-7, and Prevotellaceae at the family level and Lactobacillus at the genus level, while decreasing Bacteroidaceae, Desulfovibrionaceae, Lachnospiraceae, and Ruminococcaceae at the family level and Bacteroides, Desulfovibrio, Oscillospira, and Blautia at the genus level.\nReduced histopathological damage in recipient mice.
Reduced MPO activity, IL-1β, IL-6, TNF-α, iNOS, and COX-2 levels, and elevated IL-10 levels.
Enhanced expression of tight junction proteins ZO-1 (fold change ~2.0), occludin (fold change ~1.8), and claudin-3 (fold change ~4.0) compared to the FN group.
-
Animal Model:BALB/c mice (Male, 6-8 weeks old, LPS-induced)[3]
-
Dosage:10, 15 mg/kg
-
Administration:i.p.; single dose; 1 h before LPS modeling
-
Result:Reduced lung histopathological injury score in a dose-dependent manner, with the 15 mg/kg dose showing greater alleviation than the 10 mg/kg dose.
Decreased the lung wet-dry (W/D) weight ratio.
Reduced mRNA expression levels of Il6, Il1β, Tnfa, iNOS, Cox2, and Mpo in lung tissues.
Reduced protein secretion of IL-6, IL-1β, and TNF-α in bronchoalveolar lavage fluid (BALF).
-
Animal Model:C57BL/6 (female, 7-week-old)[5]
-
Dosage:1 mM; 2 mM
-
Administration:topical application; daily; 25 days
-
Result:Accelerated anagen entry and hair regrowth.
Significantly increased the rate of hair regeneration at both 1 mmol/L and 2 mmol/L.
Markedly promoted hair follicles to enter a state of active growth at day 6.
Markedly increased the protein levels of β-catenin, p-GSK3β, and Axin2, and greatly increased the expression of downstream target genes Lef-1 and Cyclin D1 at both mRNA and protein levels.
-
Animal Model:C57BL/6 (male, 12-week-old, 20-25 g, MPTP-induced)[6]
-
Dosage:30, 100 mg/kg/day
-
Administration:p.o.; daily; 12 days
-
Result:Reduced turning and climbing time in the pole test, rescuing 44.4% of climbing time.
Improved locomotor speed, step size, and preserved shorter run duration in Catwalk gait analysis.
Rescued shortened bilateral print positions and recovered stride length of four limbs.
Presented similar or better effect than PPX on swing speed and relieved prolonged standing time and step cycle time.
Increased TH-immunopositive fiber fluorescence intensity in the striatum but did not change TH-immunopositive cells in the SNpc.
-
Animal Model:C57BL/6 (male, 12-week-old, 20-25 g, 6-OHDA-induced)[6]
-
Dosage:100 mg/kg
-
Administration:p.o.; daily; 22 days
-
Result:Reduced climbing time by 22.2% in the pole test compared to the 6-OHDA-lesioned group.
Spent 34.2% less time to cross the beam in the balance beam test.
Regained almost 30% locomotion activity compared to the 6-OHDA group.
-
Animal Model:C57BL/6 J mice (Male, 8 weeks old, 26 g)[7]
-
Dosage:50 mg/kg
-
Administration:i.p.; once a day; 4 days
-
Result:Reduced ongoing alcohol consumption on the first treatment day and the second day after treatment, with a significant decrease in the 6-day average alcohol consumption.
Decreased the 6-day average alcohol preference and total intake.
Reduced alcohol consumption on the first, third, and fourth days of reinstatement, with a significant decline in the 4-day average consumption and preference during withdrawal.
Had no effect on alcohol consumption during relapse, but significantly decreased alcohol preference on the third reinstatement day and in the 4-day average analysis.
Chemical Information
-
CAS. Nr. 539-15-1
-
Appearance Solid
-
Molecular Weight 165.24
-
Formel C10H15NO
-
Color Off-white to light yellow
-
SMILES
OC1=CC=C(CCN(C)C)C=C1
-
Synonyms
Ordenina; Peyocactine
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
J Agric Food Chem
Chemoproteomic Profiling of Cobalamin-Independent Methionine Synthases in Plants with a Covalent Probe. [Abstract]2020 Jul 29;68(30):8050-8056. PMID: 32618189
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 250 mg/mL (1512.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 6.25 mg/mL (37.82 mM); Clear solution
This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 6.25 mg/mL (37.82 mM); Clear solution
This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Reinheit & Dokumentation
-
Data Sheet (310 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[2]. Kim SC, et al. Hordenine, a single compound produced during barley germination, inhibits melanogenesis in human melanocytes. Food chemistry. 2013 Nov 01;141(1):174-81. [Content Brief]
[6]. Li H, et al. Hordenine improves Parkinsonian-like motor deficits in mice and nematodes by activating dopamine D2 receptor-mediated signaling. Phytotherapy research : PTR. 2023 Aug;37(8):3296-3308. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.0518 mL | 30.2590 mL | 60.5180 mL | 151.2951 mL |
| 5 mM | 1.2104 mL | 6.0518 mL | 12.1036 mL | 30.2590 mL | |
| 10 mM | 0.6052 mL | 3.0259 mL | 6.0518 mL | 15.1295 mL | |
| 15 mM | 0.4035 mL | 2.0173 mL | 4.0345 mL | 10.0863 mL | |
| 20 mM | 0.3026 mL | 1.5130 mL | 3.0259 mL | 7.5648 mL | |
| 25 mM | 0.2421 mL | 1.2104 mL | 2.4207 mL | 6.0518 mL | |
| 30 mM | 0.2017 mL | 1.0086 mL | 2.0173 mL | 5.0432 mL | |
| 40 mM | 0.1513 mL | 0.7565 mL | 1.5130 mL | 3.7824 mL | |
| 50 mM | 0.1210 mL | 0.6052 mL | 1.2104 mL | 3.0259 mL | |
| 60 mM | 0.1009 mL | 0.5043 mL | 1.0086 mL | 2.5216 mL | |
| 80 mM | 0.0756 mL | 0.3782 mL | 0.7565 mL | 1.8912 mL | |
| 100 mM | 0.0605 mL | 0.3026 mL | 0.6052 mL | 1.5130 mL |
Keywords
- Hordenine
- 539-15-1
- Ordenina
- Peyocactine
- Bacterial
- p38 MAPK
- JNK
- ERK
- Akt
- Interleukin Related
- TNF Receptor
- NO Synthase
- COX
- Reactive Oxygen Species (ROS)
- Microphthalmia Associated Transcription Factor (MITF)
- Wnt
- β-catenin
- Dopamine Receptor
- Adrenergic Receptor
- 5-HT Receptor
- Serotonin Transporter
- Dopamine Transporter
- α-synuclein
- TRP-1
- tyrosinase
- MITF
- cAMP
- Nrf2
- HO-1
- TLR4
- NF-κB
- AMPK
- MAPK
- Inhibitor
- inhibitor
- inhibit